A role for NCAM in depression and antidepressant actions? (Commentary on Aonurm-Helm et al.).
Sandi
Carmen
C
Brain Mind Institute, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland.
D000818:Animals; D006801:Humans; D051379:Mice; D000928:Antidepressive Agents / Q000494:pharmacology; D001284:Atrophy / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D003863:Depression / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D005346:Fibroblast Growth Factors / Q000819:agonists / Q000378:metabolism; D009410:Nerve Degeneration / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D019006:Neural Cell Adhesion Molecules / Q000819:agonists / Q000378:metabolism; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000187:drug effects / Q000378:metabolism
D000928:Antidepressive Agents; C496349:Fgfr1 protein, mouse; D005346:Fibroblast Growth Factors; D019006:Neural Cell Adhesion Molecules; D051496:Receptor, Fibroblast Growth Factor, Type 1